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1101-42 TAXUS IV: Results From the Intravascular Ultrasound 
Substudy
Neil J. Weissman, Stephen Ellis, Mark Turco, Joel Greenberg, James Tift Mann, Michael 
Kutcher, S. Chiu Wong, Charles O'Shaughnessy, Mary Russell, Gregg W. Stone, 
Washington Hospital Center, Washington, DC
Background: The TAXUS IV multicenter, randomized, double-blind clinical trial demon-
strated that the TAXUS stent decreases clinical events and angiographic restenosis.
Methods: In order to enhanced our understanding of the relative efficacy and safety of
the TAXUS stent, a pre-specified IVUS substudy was conducted at 27 sites in 268
patients. Consecutive patients enrolled into the TAXUS IV study at these sites were man-
dated to use IVUS at implantation and follow-up. Standard IVUS imaging methods (IC
nitroglycerine, motorized pullback) and core lab volumetric analysis was performed
throughout the stent and edges.
Results: Of the 199 patients returning for a 9-month follow-up IVUS, 178 (90%) were
technically adequate for subsequent analysis (87 control, 91 TAXUS). Baseline IVUS vol-
umes (vessel, stent and lumen volume) at implantation were similar in each group. Follow
up volumes are below (table): 
The neointima reduction was uniform throughout the stent. In addition, there was no dif-
ference in the lumen loss at the margins beyond the stent edges except for a reduction of
the lumen loss for the first mm at the distal edge in the TAXUS group (p=0.004). Late
incomplete stent apposition only occurred in 2 control patients and 1 TAXUS patient
(p=0.62).
Conclusion: The TAXUS stent decreased neointima volume uniformly throughout the
stent without any negative edge effects and without any increase in late incomplete appo-
sition.
1101-43 Longitudinal Vessel Remodeling Pattern Following 
Sirolimus-Eluting Stent Implantation: Analysis of Vessel 
Integrity Throughout Target Segment
Hideaki Kaneda, Junya Ako, Yasuhiro Honda, Ryota Sakurai, Mitsuyasu Terashima, 
Shinjo Sonoda, Yoshihisa Shimada, Yoshihiro Morino, Paul G. Yock, Martin B. Leon, 
Jeffrey W. Moses, Peter J. Fitzgerald, The SIRIUS Investigators, Stanford University, 
Stanford, CA, Lenox Hill Hospital, New York, NY
Background: Previous studies of drug-eluting stents have shown asymmetric effect on
neointimal hyperplasia (i.e., greater neointima at proximal vs distal stent edge). These
results may be caused by longitudinally asymmetric drug diffusion, delivery technique
and/or margin injury. Our study objective was to assess whether vessel remodeling fol-
lowing sirolimus-eluting stent (SES) implantation is longitudinally asymmetric.
Methods: Thirty-six patients who underwent single 18 mm stent implantation (23 SES
and 13 control Bx VELOCITY) and serial (baseline and 8 month follow-up) three-dimen-
sional IVUS were enrolled in this study from the overall SIRIUS population. Five 2 mm-
subsegments were chosen from each patient: proximal/ distal adjacent or instent edge
segments within 2 mm from the stent edge and at the center of stent. Vessel (inside the
external elastic membrane) and plaque plus neointima (vessel- lumen) volume were cal-
culated and divided by length to create an average area. Serial change was calculated as
follow up - baseline measurements.
Results: The amount and pattern of plaque plus neointima area change was significantly
different between SES and control (Left Fig.). However, there wase no significant differ-
ence in remodeling between the two treatment groups nor among different segments
using two-way ANOVA (Right Fig.).
Conclusion: There was no detectable difference in the remodeling pattern of SES and
control stents, despite significant difference in plaque plus neointima distribution. 
1101-44 Effect of Everolimus-Eluting Stents in Preventing 
Neointimal Hyperplasia: An Intravascular Ultrasound 
Analysis From the FUTURE II Trial
Shinjo Sonoda, Eberhard Grube, Yoshihisa Shimada, Ali H.M Hassan, Yasuhiro Honda, 
Paul G. Yock, Charles Chan, Hidehiko Honda, Saibal Kar, Karl E. Hauptmann, Hans 
Storger, Alexandra J. Lansky, Peter J. Fitzgerald, The FUTURE II Investigators, Stanford 
University Medical Center, Stanford, CA, Heart Center Siegburg, Siegburg, Germany
Background: FUTURE II is a prospective, randomized, multicenter, double-blind trial
comparing everolimus-eluting stents (EES), coated with a bioabsorbable polymer, to con-
ventional metallic stents (MS). This study includes a more restenosis-prone lesion subset
than FUTURE I. The purpose of this IVUS substudy was to investigate the antiprolifera-
tive efficacy of EES compared to MS in this more complex lesion subset.
Methods and Results: To date, serial 3-D IVUS analyses (baseline and 6 months follow-
up) are available in 41 patients. To adjust volume data to different stent lengths, volume
index was calculated as volume divided by stent length (VVI: vessel volume index, SVI:
stent volume index, LVI: lumen volume index). Percent neointimal volume (%NV) was
defined as neointimal volume divided by stent volume. At baseline, EES achieved stent
expansion similar to MS. VVI within the stented segment and SVI were not different
between groups either at baseline or at follow-up. LVI was also comparable between
groups at baseline. However, LVI at follow-up was significantly larger in EES than in MS
(P<0.05) and %NV was significantly lower in EES than in MS (P<0.0001, 95% reduction).
There was no evidence of unhealed dissections or late stent malapposition in either
group.
Conclusion: Everolimus-eluting stents demonstrated marked antiproliferative efficacy
compared to MS with no evidence of IVUS-detected adverse effects. 
1101-45 Contribution of Stent Underexpansion to Target Lesion 
Revascularization After Sirolimus-Eluting Stenting for 
In-Stent Restenosis
Kenichi Fujii, Yoshio Kobayashi, Gary S. Mintz, Hideo Takebayashi, Takenori Yasuda, 
David Jacoboff, Issam Moussa, Roxana Mehran, George Dangas, Alexandra Lansky, 
Edward Kreps, Michael Collins, Gregg W. Stone, Martin B. Leon, Jeffrey W. Moses, 
Cardiovascular Research Foundation, New York, NY
Background: Sirolimus-eluting stents (SES) strongly suppresses neointimal hyperplasia
and prevents target lesion revascularization (TLR) in de novo lesions. However, the effi-
cacy of SES in the treatment of in-stent restenosis (ISR) is less certain. Minimum stent
area (MSA) after stenting is a predictor of TLR. We investigated the relationship between
stent underexpansion and TLR after SES treatment of ISR.
Methods: In 40 ISR lesions treated with SES, 3-D intravascular ultrasound (IVUS) analy-
sis was performed. Stent and reference segments were measured every 1mm, and vol-
umes were calculated using Simpson’s rule. Stent underexpansion was MSA <5.0 mm2
and <80% of the average reference lumen. A residual edge lesion was stent edge plaque
burden (plaque/external elastic membrane [EEM]) >50%. Eight lesions required TLR; 32
did not.
Results: Stent underexpansion was observed in 6 TLR lesions (75%) and 11 non-TLR
lesions (34%, p=0.04). A gap between stents was detected in 3 TLR lesions (38%) and 1
non-TLR lesion (3%, p=0.01). Multivariate analysis identified stent underexpansion as
the only independent predictor of TLR (p=0.04).
Conclusions: SES fail in 25% of patients after treatment of ISR. IVUS analysis shows
that stent underexpansion, in particular, is associated with failure after SES implantation
to treat ISR.
CONTROL TAXUS p-value
Vessel vol (mm3) 286 288 0.92
Stent vol (mm3) 147 150 0.66
Lumen vol (mm3) 106 131 0.001
Neointima vol (mm3) 41 18 <0.001
% vol obstruction 29.4% 12.2% <0.001
EES MS P-value
Baseline
VVI, mm3/mm 15.6 ± 5.8 16.6 ± 4.7 0.53
SVI, mm3/mm 7.5 ± 2.2 7.9 ± 2.2 0.60
6 months follow-up
VVI, mm3/mm 15.7 ± 5.7 17.0 ± 4.9 0.46
SVI, mm3/mm 7.7 ± 2.1 7.8 ± 2.2 0.82
LVI, mm3/mm 7.6 ± 2.1 6.2 ± 2.3 < 0.05
%NV, % 1.2 ±1.9 22.0 ±16.0 <0.0001
